HCA — HCA Healthcare, Inc.

Sentiment is mixed: Q2 revenue grew 8.7% to $20.23B and adjusted EPS beat, yet the FY26 EPS guidance cut to $28.70-$30.50 triggered multiple analyst price-target reductions. The stock is still rated a consensus Buy (29 Buy, 15 Hold, 2 Sell), but the market is waiting to see if the payer-mix damage is contained.

Revenue growth is actually accelerating: Q2 2026 revenue of $20.23B was +8.7% YoY versus +6.4% in Q2 2025, with the last several quarters in the mid-to-high single-digit growth range. The stress is on profitability: operating margin was 15.2% in Q2 2026 and 15.0% in Q1 2026, down from 16.3% in Q4 2025 and 15.9% in Q2 2025, reflecting labor and payer-mix pressure. FY26 guidance midpoint of ~$6.5B net income implies a decline from 2025's ~$6.78B, so the underlying story is healthy volumes with a rolling-over earnings year.

As of 2026-08-27, HCA trades at roughly 14.0x trailing EPS and ~14.2x forward EPS of ~$29.5, versus its 5-year average P/E of 13.63x—basically fair, not cheap. Price-to-sales of 1.16x is below the 5-year average of 1.25x, but that is offset by expected flat-to-down earnings and negative stockholders' equity. The 0.57 PEG ratio is misleading because it embeds an unrealistic growth expectation; the forward revenue estimate implies only modest growth.

The stock has already fallen ~24% from its 52-week high of $556.52, so much of the guidance-cut bad news is in the price. But at ~14x forward earnings, it is not discounting an imminent recovery either—it is pricing in a flat-to-down EPS year. If the ACA/Medicaid headwind stabilizes and labor costs ease, there is room toward the $445-$455 analyst target; if payer mix keeps deteriorating, the $369 low target becomes relevant. This is a show-me story, not a deep-value setup.

As of 2026-08-27, RSI(14) was 56.17, price was 1.51% above the 20-day and 4.92% above the 50-day, but 7.59% below the 200-day. That is a short-term bounce inside a longer-term downtrend—neutral momentum, not oversold, and no confirmed reversal. Better entry timing would come from a reclaim of the 200-day or a retest of the lower $380-$400 support zone.

• ACA enhanced-subsidy expiration and Medicaid redeterminations: HCA quantified a $1.0-$1.2B hit to 2026 revenue/payer mix.
• Interest-rate trajectory: HCA carries ~$43.5B of debt, so lower rates help refinancing and free cash flow; higher rates hurt.
• Labor cost inflation: salaries and benefits rose to $8.3B in Q2 2026, up from $8.1B in Q2 2025, capping margin expansion.
• Hospital utilization and elective volumes: same-facility admissions +2.5% and ER visits +3.6% show healthy demand, but reimbursement mix determines margins.

• Q3 2026 earnings in late October: whether HCA holds the reduced FY26 guidance range or needs to cut again.
• Evidence that ACA/Medicaid payer-mix deterioration is stabilizing rather than accelerating.
• Capital deployment: continued buybacks/dividends and capacity expansions (e.g., the Cape Coral hospital) signaling cash-flow confidence.
• Fed rate cuts or successful debt refinancing reducing interest expense on the ~$43.5B debt load.

• Further payer-mix deterioration and rising uncompensated care from ACA exchange subsidy changes.
• Persistent labor/staffing cost inflation and wage negotiations pressuring operating margins.
• High leverage and negative stockholders' equity (-$6.6B) reduce financial flexibility, especially if rates stay elevated.
• Regulatory/reimbursement cuts, including Medicare rate updates and site-neutral payment policies.

HCA is a high-quality hospital operator with 18.5% ROIC, strong free cash flow, and accelerating volume growth, but the next 12 months are an earnings downcycle: guidance calls for lower net income, payer-mix headwinds are quantified at $1B+, and the balance sheet is stretched by negative equity. At $419, the valuation is roughly fair rather than cheap, and that is not enough compensation for the deteriorating near-term fundamentals—so the stock is not an attractive entry right now.

Blended valuation: ~13.5x forward EPS of ~$29.50 gives ~$398, while ~9x EV/EBITDA on roughly $15B EBITDA less ~$42.5B net debt gives ~$427; averaging those and leaning down for the weak balance sheet and flat earnings trajectory yields ~$413. This is below both the current price and the $455 consensus target, reflecting the cautious near-term earnings outlook.